Search
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnLorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsLevoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalIn vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. … However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Lanolin
go.drugbank.com/drugs/DB11112ApprovedThe US federal code of regulations states that lanolin in the concentration range of 12-50% may be included in over the counter skin ointments [L2583]. … Lanolin is the purified, secreted product of the sheep sebaceous glands [L2584]. Lanolin primarily consists of long-chain waxy esters, or sterol esters, that lack glycerides.
Mixtures: Veradex-E, Huile De Bain TherapeutiqueLamivudine
go.drugbank.com/drugs/DB00709ApprovedInvestigationalA reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. … It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Mixtures: LAMIHOPE-T (LAMIVUDINE 300MG AND TENOFOVIR DISOPROXIL FUMARATE 300MG FILM-COATED TABLETS), TENOLAM-ECategories: Antivirals used in combination for the treatment of HIV infectionsRotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalLike other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. … In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsDoxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. … [L5971] However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.[L5974]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsProducts: DOXEPIN DURA T 50MG, DOXEPIN DURA T 100MGXenon-133
go.drugbank.com/drugs/DB09315ApprovedXenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.
Synonyms: Xenon (133 xe), Xenon Xe 133Products: Xenon, Xe-133Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigational[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Categories: Sex Hormones and Modulators of the Genital SystemEnalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalEnalaprilat is the active metabolite of the orally available pro-drug, [enalapril]. … Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth.
Categories: Agents Acting on the Renin-Angiotensin SystemBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalCompared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists